Adagene Inc Adr (ADAG)

May 03, 2026

Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT) - The Globe and Mail

May 03, 2026

Apr 26, 2026

Adagene announces pricing of $70M public offering of ADS - MSN

Apr 26, 2026

Apr 24, 2026

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat

Apr 24, 2026

Apr 21, 2026

ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill

Apr 21, 2026

Apr 20, 2026

Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co

Apr 20, 2026

Apr 18, 2026

Qinghai Zhao Net Worth (2026) - GuruFocus

Apr 18, 2026

Apr 17, 2026

Adagene reports trial data for cancer drug muzastotug combos By Investing.com - Investing.com South Africa

Apr 17, 2026

Apr 17, 2026

Adagene reports trial data for cancer drug muzastotug combos - Investing.com

Apr 17, 2026

Apr 17, 2026

Experimental Adagene drug lifts liver cancer response to 66.7% - Stock Titan

Apr 17, 2026

Apr 17, 2026

Adagene (NASDAQ: ADAG) shows strong AACR 2026 data for muzastotug combo therapies - Stock Titan

Apr 17, 2026

Apr 16, 2026

Adagene Looks Attractive With ADG126 And Validating Partnerships (NASDAQ:ADAG) - Seeking Alpha

Apr 16, 2026

Apr 15, 2026

Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Apr 15, 2026

Apr 14, 2026

Adagene appoints Peter Lebowitz to advisory board - Investing.com

Apr 14, 2026

Apr 14, 2026

Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India

Apr 14, 2026

Apr 14, 2026

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget

Apr 14, 2026

Apr 09, 2026

Analysts Offer Predictions for Adagene FY2026 Earnings - MarketBeat

Apr 09, 2026

Apr 07, 2026

H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa

Apr 07, 2026

Apr 07, 2026

H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com

Apr 07, 2026

Apr 06, 2026

Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat

Apr 06, 2026

Apr 06, 2026

Guggenheim raises Adagene stock price target on cancer drug data - Investing.com

Apr 06, 2026

Apr 06, 2026

Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa

Apr 06, 2026

Apr 03, 2026

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm

Apr 03, 2026

Apr 03, 2026

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm

Apr 03, 2026

Apr 03, 2026

Leerink raises Adagene stock price target to $8 on combination data - Investing.com India

Apr 03, 2026

Apr 02, 2026

[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net

Apr 02, 2026

Apr 02, 2026

Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa

Apr 02, 2026

Apr 02, 2026

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com

Apr 02, 2026

Apr 02, 2026

Adagene sets $3.75 per ADS price for $70M offering - MSN

Apr 02, 2026

Apr 02, 2026

Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India

Apr 02, 2026

Apr 02, 2026

Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks

Apr 02, 2026

Apr 02, 2026

Adagene prices $70 million public offering at $3.75 per ADS - Investing.com

Apr 02, 2026

Apr 02, 2026

Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - TipRanks

Apr 02, 2026

Apr 02, 2026

Adagene reports 31% response rate in colorectal cancer trial By Investing.com - Investing.com India

Apr 02, 2026

Apr 02, 2026

Adagene reports 31% response rate in colorectal cancer trial - investing.com

Apr 02, 2026

Apr 02, 2026

Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - Stock Titan

Apr 02, 2026

Apr 02, 2026

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget

Apr 02, 2026

Apr 02, 2026

Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan

Apr 02, 2026

Apr 02, 2026

Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire

Apr 02, 2026

Apr 02, 2026

Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - Stock Titan

Apr 02, 2026

Apr 02, 2026

Why Is ADAG Stock Tanking Today? - Stocktwits

Apr 02, 2026

Apr 01, 2026

Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat

Apr 01, 2026

Apr 01, 2026

Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028 - TipRanks

Apr 01, 2026

Apr 01, 2026

Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends - Stock Titan

Apr 01, 2026

Apr 01, 2026

Regulatory pressure around China puts Adagene (ADAG) Nasdaq listing at risk - Stock Titan

Apr 01, 2026

Mar 30, 2026

Empowering Investor Success - Morningstar

Mar 30, 2026